Korro Bio
KRRO
48 hedge funds and large institutions have $28.1M invested in Korro Bio in 2022 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 14 reducing their positions, and 10 closing their positions.
1,892% more call options, than puts
Call options by funds: $239K | Put options by funds: $12K
99% more capital invested
Capital invested by funds: $14.1M → $28.1M (+$14M)
0.03% less ownership
Funds ownership: 0.45% → 0.42% (-0.03%)
13% less funds holding
Funds holding: 55 → 48 (-7)
57% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 14
60% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$37.1K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$36.9K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$36K |
| 4 |
DSC
Duncker Streett & Co
St. Louis,
Missouri
|
+$29.5K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$23.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$574K |
| 2 |
E
Ergoteles
New York
|
-$190K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$106K |
| 4 |
Millennium Management
New York
|
-$79.7K |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$45K |
KRRO Hedge Fund Activity: Q4 2022 in Review
48 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Korro Bio (KRRO) for Q4 2022, worth a combined $28.1M — up 99% from $14.1M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of KRRO and 4 opened new positions — a net loss of 6 holders — while 14 trimmed existing stakes and 6 added.
The largest buyer was GSA Capital Partners, adding an estimated $37.1K. The largest seller was BlackRock, cutting an estimated $574K.
- 48 institutional investors held Korro Bio (KRRO) as of Q4 2022, down from 55 in Q3 2022.
- Funds reported $28.1M of Korro Bio stock for Q4 2022, up 99% quarter-over-quarter.
- 4 funds opened new Korro Bio positions in Q4 2022 and 10 closed out, a net change of -6 holders.
- The largest Korro Bio buyer in Q4 2022 was GSA Capital Partners, an estimated $37.1K added.
- The largest Korro Bio seller in Q4 2022 was BlackRock, an estimated $574K sold.
Based on aggregated 13F filings for Q4 2022.